

Claire Murphy, MBiolSci,
MSc

Sira Nanthapaisal, MD
Kimberly Gilmour, PhD

Sue Laurent, FRCPCH

Felice D'Arco, MD

Cheryl Hemingway,
MBBS, PhD

Paul Brogan, MB ChB,
PhD

Despina Eleftheriou,
MBBS, PhD

PROGRESSIVE NEUROLOGIC DISORDER: INITIAL MANIFESTATION OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS

OPEN

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of pathologic immune activation occurring as a primary genetic disorder, or in association with infections, malignancies, or rheumatologic disorders (secondary HLH).¹ CNS inflammation has been observed in both forms of HLH, but has not been previously reported as the presenting sole manifestation of the disease.²

Case report. A 14-year-old Caucasian female presented with a 3-month history of headaches, progressive right-sided convergent squint, dysarthria, gait abnormality with progressive difficulty in climbing up the stairs and being able to stand, and hyperesthesia involving her left arm and leg. She had a long-standing history of pervasive refusal disorder for which she was receiving psychiatric support. Ophthalmology examination revealed a VI cranial nerve palsy and papilledema. She had normal tone, with decreased power in upper and lower limbs and absent reflexes, and no ankle clonus; there was no hepatosplenomegaly and no peripheral lymphadenopathy detected. Brain and spine MRI revealed leptomeningeal enhancement and generalized white matter lesions, in addition to mid-cervical cord contrast-enhancing lesions (figure, A–D). EMG demonstrated motor and sensory neuropathy; sural nerve biopsy showed axonal degeneration with mild inflammatory changes but no vasculitis. Hemoglobin was 14.7 g/dL (reference range [RR] 12–16 g/dL), platelet count $261 \times 10^9/L$ (RR 150–450 $\times 10^9/L$), white cell count $5.63 \times 10^3/L$ (RR 4.0–11.0 $\times 10^3/L$), alanine transaminase 17 U/L (RR 10–45 U/L), and fibrinogen 2.8 g/L (RR 1.7–4.0 g/L); ferritin was not tested. Oligoclonal bands were positive on CSF examination, suggesting a CNS inflammatory process; other extensive investigations excluded infective, rheumatologic, metabolic, and malignant causes. She was considered to have an unclassified neuroinflammatory disease and was treated empirically with IV immunoglobulin (1 g/kg) and corticosteroids (IV methylprednisolone at 30 mg/kg

over 3 days and oral prednisolone 2 mg/kg/d tapered over 8 weeks), with resolution of white matter lesions and improvement of the dysarthria, squint, papilledema, headaches, and hyperesthesia, although her mobility remained impaired despite intense physiotherapy. Thirteen months later, she developed a generalized seizure requiring admission to intensive care, with fever and pancytopenia (hemoglobin at 7.6 g/dL, platelet count $55 \times 10^9/L$, and white cell count $3.5 \times 10^3/L$). Blood PCR for Epstein-Barr virus was positive at 850,000 copies/mL. She was thought to have viral-induced secondary HLH on the background of a neuroinflammatory syndrome. She was treated with IV methylprednisolone at 30 mg/kg/d for 3 days, oral prednisolone 2 mg/kg/d tapered over 4 months, rituximab (375 mg/m² weekly for 4 weeks), and mycophenolate mofetil (1,200 mg/m²/d).


Whole exome sequencing revealed known pathogenic compound heterozygous mutations in *UNC13D*: exon 10 (c.C817T; p.R273X) and exon 14 (c.G1241T; p.R414L),^{3,4} confirmed using Sanger sequencing (figure, E; e-Methods and table e-1 on the *Neurology*[®] Web site at Neurology.org), Munc 13-4 protein was absent (figure, F), and defective CD8 T cell degranulation was demonstrated (figure, G; e-Methods). Based on these results, the patient was fast-tracked to allogeneic hematopoietic stem cell transplantation. At the time of writing, she remains well with no further hematologic and/or neurologic manifestations of HLH at 4 months after allogeneic hematopoietic stem cell transplantation.

Discussion. We report a case of primary HLH that rather atypically presented with an isolated neurologic disorder. We suggest that HLH should be included in the differential diagnosis of unclassified progressive neuroinflammatory disease, even in the absence of pancytopenia. Functional screening assays, such as quantification of T and NK cell degranulation, and intracellular perforin staining, can be used to promptly identify patients with primary HLH and guide management.⁵

Neurologic signs are present in up to 63% of children with primary HLH at disease onset²; the majority, however, also have other classic HLH manifestations. Our patient presented with an

Supplemental data
at Neurology.org

Figure Imaging findings, Sanger sequencing, Munc protein expression, and CD107a degranulation assay in a 14-year-old female with progressive neurologic disorder due to primary hemophagocytic lymphohistiocytosis



(A) Coronal fluid-attenuated inversion recovery-weighted MRI of the brain, (B) sagittal T2-weighted imaging of the cervicothoracic spine, and (C) axial T2-weighted imaging of the brain, showing bilateral lesions in the brain (internal capsules, globi pallidi, subthalamic nuclei, deep white matter), as well as mid-cervical spine lesions. (D) Axial postcontrast T1-weighted imaging at the level of the cerebellum revealed bilateral diffuse leptomeningeal enhancement. (E) Sanger sequencing chromatogram of *UNC13D* gene showing compound heterozygous mutations in exon 10 (c.C817T; p.R273X) and exon 14 (c.G1241T; p.R414L) for the same patient. (F) Western blot analysis in patient-derived peripheral blood mononuclear cells shows absence of Munc 13-4 protein relative to a healthy control. (G) Flow cytometric figures show absent percentage increase in CD107a-positive cells in patient-derived CD8 T cells following stimulation with anti-CD3 antibody in relation to a healthy control.

isolated progressive neurologic disorder, 13 months before more typical HLH features.² CNS involvement in HLH can radiologically mimic neuroinflammatory disorders including multiple sclerosis and acute disseminated encephalomyelitis.⁶ Since diagnostic delay may result in fatalities or irreversible neurologic sequelae,² clinicians should be aware that unclassified neuroinflammatory diseases could evolve into full-blown HLH.

This late development of more typical HLH manifestations in our patient is intriguing. The heterozygous R414L mutation has been described in 2 patients with compound heterozygous mutations in *UNC13D* with late-onset primary HLH associated with encephalopathy in the context of other typical features of HLH.³ Patients with at least one allele bearing a nonsynonymous rather than a disruptive mutation may develop symptoms at a significantly older age, suggesting that residual

degranulation function allows some defensive capacity.⁷

Our case report also highlights the utility of next-generation sequencing in making early genetic diagnoses and enabling targeted treatments.⁷

From the Infection, Immunity, Inflammation and Physiological Medicine Programme (C.M., S.N., P.B., D.E.), University College London Institute of Child Health, UK; Faculty of Medicine (S.N.), Thammasat University, Thailand; Immunology (K.G.), Neuroradiology Department (F.D.), and Neurology Department (C.H.), Great Ormond Street Hospital NHS Foundation Trust, London; and Paediatric Department (S.L.), Royal Free Hospital NHS Foundation Trust, London, UK.

Author contributions: Claire Murphy: data analysis, Sanger sequencing, writing of manuscript. Sira Nanthapaisal: whole exome sequencing, data analysis, review of the manuscript. Kimberly Gilmour: data collection, review and final approval of the manuscript. Sue Laurent: data collection, review and final approval of the manuscript. Felice D'Arco: imaging data collection, review and final approval of the manuscript. Cheryl Hemingway: data collection, review and final approval of the manuscript. Paul Brogan: data collection, review and final approval of

the manuscript. Despina Eleftheriou: design of the study, data acquisition, analysis, writing and final approval of the manuscript.

Study funding: Claire Murphy and Sira Nanthapaisal are supported by Rosetrees Trust (grant M8F1CD1). Kimberly Gilmour is partially supported by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. Despina Eleftheriou is supported by Arthritis Research UK (grant 20164).

Disclosure: C. Murphy is receiving research support from Rosetrees Trust. S. Nanthapaisal is receiving research support from Rosetrees Trust. K. Gilmour has received research support from the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. S. Laurent and F. D'Arco report no disclosures relevant to the manuscript. C. Hemingway has received research support from Multiple Sclerosis Society and Action research, and honoraria from Biogen Idec and Merck Serono Bayer. P. Brogan has received institutional grants from Sobi, Novartis, and Roche and consultancy fees from Roche and Sobi. D. Eleftheriou is receiving research support from ARUK and has received an institutional grant from Roche. Go to Neurology.org for full disclosures. The Article Processing Charge was paid by Arthritis UK.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received December 1, 2015. Accepted in final form February 24, 2016.

Correspondence to Claire Murphy: Claire.Murphy.13@ucl.ac.uk

© 2016 American Academy of Neurology

1. Janka G. Familial and acquired haemophagocytic lymphohistiocytosis. *Eur J Pediatr* 2007;166:95–109.
2. Deiva K, Mahlaoui N, Beaudonnet F, et al. CNS involvement at the onset of primary haemophagocytic lymphohistiocytosis. *Neurology* 2012;78:1150–1156.
3. Santoro A, Cannella D, Bossi G, et al. Novel Munc13-4 mutations in children and young adult patients with haemophagocytic lymphohistiocytosis. *J Med Genet* 2006;43:953–960.
4. Stadt U, Beutel K, Kolberg S, et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. *Hum Mutat* 2006;27:62–68.
5. Bryceson Y, Pende D, Maul-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial haemophagocytic syndromes. *Blood* 2012;119:2754–2763.
6. Weisfeld-Adams JD, Frank Y, Havalad V, et al. Diagnostic challenges in child with familial haemophagocytic lymphohistiocytosis type 3 (FHLH3) presenting with fulminant neurological disease. *Childs Nerv Syst* 2009;25:153–159.
7. Sieni E, Cetica V, Santoro A, et al. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3. *J Med Genet* 2011;48:343–352.

Frank A. Wollenweber,
MD

Jan Remi, MD

Axel Bauer, MD

Hans Theiss, MD

Steffen Massberg, MD

Maximilian Patzig, MD

Claudius Faber, MD

Marianne Dieterich, MD

Hendrik Janssen, MD

THROMBECTOMY RECOVERS AN AORTIC WALL FRAGMENT FROM MIDDLE CEREBRAL ARTERY IMMEDIATELY AFTER TAVI

An 80-year-old woman underwent transcatheter aortic valve implantation (TAVI) using an Edward Sapien S3 device to treat symptomatic severe aortic stenosis, with a 0.8 cm² aortic valve area.

After valve implantation, the patient developed sudden onset of global aphasia and severe right-sided hemiparesis. The instantly performed precontrast cranial CT scan showed no signs of ischemia, but CT perfusion imaging demonstrated a severe impairment of blood supply in the left cerebral hemisphere in accordance with the acute clinical symptoms (figure). Further CT angiography suggested a middle cerebral artery (MCA) occlusion. After a brief interdisciplinary evaluation of the case, the patient was rapidly transferred to the department of neuroradiology, where a conventional angiography confirmed the diagnosis of an acute MCA occlusion. An immediate thrombectomy (preset 4 × 20 stent retriever and Navien 58 distal-access catheter) retrieved a solid piece of tissue measuring 2 × 0.5 × 0.1 cm. Neither thrombolysis nor heparin was administered during mechanical thrombectomy as the partial thromboplastin time was still elevated to 126 seconds from the recent TAVI procedure. The clinical symptoms of the patient were relieved directly after flow restoration to a mild expressive aphasia and

a latent palsy of the right leg. A follow-up cranial CT scan 3 days later did not detect any ischemic infarction. Histopathologic examination of the recovered object demonstrated endothelialized tissue most likely representing internal parts of an arterial vessel wall with atherosclerotic changes. Of note, no adjacent thrombus could be detected in the Elastica-van-Gieson stain (figure). Echocardiography demonstrated the implanted aortic valve in place with good function.

Recently, TAVI has become a standard treatment for elderly patients with severe aortic stenosis and a high surgical risk.¹ While clinically manifest strokes as a complication have been estimated to occur in up to 5% of TAVI procedures,² clinically silent cerebral MRI lesions can be detected in over 80% of cases.³ This is of special importance as a periprocedural stroke is associated with both dependency and mortality.⁴ The use of specific emboli protection systems may be able to lower the rate of periprocedural strokes, but needs to be established in larger case series.⁵ To our knowledge, no specific treatment guidelines on large periprocedural strokes exist. Current studies prove mechanical thrombectomy to be the most effective treatment in patients with thromboembolic proximal artery occlusion.⁶ We could identify one previous case report in the literature that describes a recovery of a soft thrombus by mechanical thrombectomy after TAVI.⁷ This case report demonstrates for the